Uncategorized
Subgroups in VIEW studies maintained visual improvements with less dosing frequency
After a year of fixed treatment in the VIEW studies, 50% of patients with neovascular age-related macular degeneration who received 2 mg of intravitreal aflibercept could be extended to dosing every 12 weeks during the second year compared with 43% of patients who received 0.5 mg of ranibizumab, according to a presentation at the Macula Society annual meeting in Singapore.The subgroup of patients that received dosing every 12 weeks during year 2 as opposed to more frequent dosing had smaller choroidal neovascularization area and lesion size, a lower proportion of (Read more...)